echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Lancet Diabetes Endo: The effect of dapagliflozin on urine protein in chronic kidney disease patients with type 2 diabetes

    Lancet Diabetes Endo: The effect of dapagliflozin on urine protein in chronic kidney disease patients with type 2 diabetes

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The reduction of proteinuria in patients with chronic kidney disease is associated with a lower risk of subsequent renal failure
    .
    The SGLT2 inhibitor dapagliflozin can significantly reduce proteinuria in patients with type 2 diabetes with normal or close to normal renal function


    .


    diabetes

    The DAPA-CKD study is a multi-center, double-blind, placebo-controlled randomized trial conducted in 386 locations in 21 countries to evaluate the effect of dapagliflozin on proteinuria in patients with chronic kidney disease with type 2 diabetes Impact
    .

    Recruited patients with confirmed chronic kidney disease (eGFR=25-75 mL/min·1.
    73 m2, urinary albumin-creatinine ratio (UACR)=200~5000 mg/g[22.
    6~565.
    6 mg/mmol]), and randomly divided them into daglie Net group (dapagliflozin 10 mg/day) or placebo group
    .
    The intended exploratory endpoint is a change in proteinuria


    .


    From February 2, 2017 to April 3, 2020, a total of 4304 patients were recruited and randomly assigned to the dapagliflozin group (n=2152) or placebo group (n=2152)
    .
    The median UACR was 949 mg/g (range 477~1885)


    .


    Compared with placebo, dapagliflozin patients can UACR geometric mean of 29.


    Compared with placebo, the effect of dapagliflozin on geometric mean UACR

    Compared with placebo, the effect of dapagliflozin on geometric mean UACR

    In 3860 patients with a baseline UACR ≥ 300 mg/g, dapagliflozin increased the possibility of UACR staging (from large proteinuria to microalbuminuria or no proteinuria) (hazard ratio [HR] 1.
    81 , 95% CI 1.
    60~2.
    05)
    .
    In 3820 patients with a baseline UACR <300 mg/g, dapagliflozin reduced the risk of UACR stage progression (HR 0.


    41, 0.


    In 3860 patients with a baseline UACR ≥ 300 mg/g, dapagliflozin increased the likelihood of UACR staging (from massive proteinuria to microalbuminuria or no proteinuria) at baseline UACR ≥ 300 mg/g.


    In patients with chronic kidney disease with or without type 2 diabetes, dapagliflozin can still significantly reduce proteinuria, and the relative reduction in patients with type 2 diabetes is even greater in patients with type 2 diabetes with or without chronic kidney disease.


    Original source:

    Niels Jongs, et al.


    Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.